Study of Self or Clinic Administration of DepoProvera

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

Depot medroxyprogesterone acetate (DepoProvera) is an acceptable form of contraception for many women. However, difficulty in access may cause many women to discontinue use, often without the use of another effective method of contraception, thereby leaving them vulnerable to unintended pregnancy. This study will randomly assign women who present for contraceptive services to two groups: self or clinic administered SC DMPA. The participants will be followed for one year to compare continuation rates, acceptability, cost effectiveness, evidence of skin changes, and need for continued support between the two groups.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Carolyn L. Westhoff
• Collaborators: Family Planning Fellowship; Pfizer
• Treatments: Medroxyprogesterone; Medroxyprogesterone Acetate

Criteria

Inclusion Criteria:

1. age greater than or equal to 18 years

2. seeking DMPA for contraception

3. English or Spanish speaking

4. consistent access to a working telephone

5. availability for follow up for one year

Exclusion Criteria:

1. suspected or continuing pregnancy

2. undiagnosed vaginal bleeding

3. known or suspected breast cancer

4. acute liver disease

5. known hypersensitivity to medroxyprogesterone acetate or any other components of DMPA

6. desire for pregnancy within one year